Psoriasis and Cardiovascular Disease.
Shahwan, Kathryn T, and Alexa B Kimball. 2015. “Psoriasis and Cardiovascular Disease.”. The Medical Clinics of North America 99 (6): 1227-42.
Search
Search results
717 results found
Pregnancy outcomes in patients with psoriasis, psoriatic arthritis, or axial spondyloarthritis receiving ixekizumab.
Egeberg, A, L Iversen, A B Kimball, S Kelly, E Grace, H Patel, W Xu, G Gallo, E Riedl, and S R Feldman. 2022. “Pregnancy Outcomes in Patients With Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis Receiving Ixekizumab.”. The Journal of Dermatological Treatment 33 (5): 2503-9.
Psoriasis and Mental Health Workshop Report: Exploring the Links between Psychosocial Factors, Psoriasis, Neuroinflammation and Cardiovascular Disease Risk.
Kleyn, Elise, Peter S Talbot, Nehal N Mehta, Francesca Sampogna, Chris Bundy, Darren M Ashcroft, Alexa B Kimball, et al. 2020. “Psoriasis and Mental Health Workshop Report: Exploring the Links Between Psychosocial Factors, Psoriasis, Neuroinflammation and Cardiovascular Disease Risk.”. Acta Dermato-Venereologica 100 (1): adv00020.
Assessing the Impact of Improvements in PASI and Itch Scores on Patients' Quality of Life in the Treatment of Psoriasis.
Yosipovitch, Gil, Yan Dong, Russel Burge, Baojin Zhu, David Shrom, and Alexa B Kimball. 2019. “Assessing the Impact of Improvements in PASI and Itch Scores on Patients’ Quality of Life in the Treatment of Psoriasis.”. Acta Dermato-Venereologica 99 (11): 1031-32.
Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape.
Krueger, James G, John Frew, Gregor B E Jemec, Alexa B Kimball, Brian Kirby, Falk G Bechara, Kristina Navrazhina, et al. 2024. “Hidradenitis Suppurativa: New Insights into Disease Mechanisms and an Evolving Treatment Landscape.”. The British Journal of Dermatology 190 (2): 149-62.
Efficacy and Safety of Risankizumab for the Treatment of Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled Trial.
Kimball, Alexa B, Errol P Prens, Thierry Passeron, Emanual Maverakis, Irina Turchin, Stefan Beeck, Leonidas Drogaris, et al. 2023. “Efficacy and Safety of Risankizumab for the Treatment of Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled Trial.”. Dermatology and Therapy 13 (5): 1099-1111.
Advances in biologic and small molecule therapies for hidradenitis suppurativa.
Chen, Stella X, Charlotte Greif, Ruby S Gibson, Martina L Porter, and Alexa B Kimball. 2022. “Advances in Biologic and Small Molecule Therapies for Hidradenitis Suppurativa.”. Expert Opinion on Pharmacotherapy 23 (8): 959-78.
Hidradenitis suppurativa disease course during pregnancy and postpartum: a retrospective survey study.
Prens, L M, M L Porter, K T Savage, P Salian, B Horváth, and A B Kimball. 2021. “Hidradenitis Suppurativa Disease Course During Pregnancy and Postpartum: A Retrospective Survey Study.”. The British Journal of Dermatology 185 (5): 1072-74.
HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study.
Kimball, A B, J M Sobell, C C Zouboulis, Y Gu, D A Williams, M Sundaram, H D Teixeira, and G B E Jemec. 2016. “HiSCR (Hidradenitis Suppurativa Clinical Response): A Novel Clinical Endpoint to Evaluate Therapeutic Outcomes in Patients With Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2 Adalimumab Study.”. Journal of the European Academy of Dermatology and Venereology : JEADV 30 (6): 989-94.
Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: a chart-verified case-control analysis.
Shlyankevich, Julia, Allison J Chen, Grace E Kim, and Alexandra B Kimball. 2014. “Hidradenitis Suppurativa Is a Systemic Disease With Substantial Comorbidity Burden: A Chart-Verified Case-Control Analysis.”. Journal of the American Academy of Dermatology 71 (6): 1144-50.